A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...
Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.
Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid ...
“This therapy was well tolerated as a frontline treatment for mHLH and helped us to gently control the disease using a precise approach, which enabled us to deliver treatment for the underlying ...
Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing ...
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback